ANGLE

ANGLE’s HER2 testing service could support longitudinal monitoring and the accuracy of subject stratification in your clinical trial. HER2+ circulating tumour cells are potential prognostic markers in metastatic breast cancer. Harnessing advanced techniques like immunofluorescence (IF) staining and fluorescence in situ hybridisation (FISH), our approach has the potential to enhance longitudinal monitoring, predict therapeutic responses, and optimise subject selection in clinical research Click here to learn more: https://lnkd.in/eeXbdgVk For Research Use Only. Not for Use In Diagnostic Procedures. #CancerResearch #HER2 #LiquidBiopsy

New research is redefining the role of circulating tumour cells (CTCs) for longitudinal patient monitoring in early prostate cancer.  Using the Parsortix® technology, the Comprehensive Cancer Centre at the Medical University of Vienna has demonstrated the potential for multi-marker analysis of CTCs in early and metastatic prostate cancer.   Access the research: https://lnkd.in/eiuAm2Vx  #Oncology #ProstateCancer #LiquidBiopsy  

Strengthen your breast cancer research with critical HER2 insights for longitudinal monitoring. HER2 status changes with breast cancer progression and is associated with poor prognosis. Our minimally invasive HER2 testing service supports the precise identification and quantification of HER2 protein expression and gene amplification in circulating tumour cells, facilitating enhanced subject stratification in clinical trials, and effective longitudinal monitoring. Discover how our approach could enhance your clinical research: https://lnkd.in/eeXbdgVk For Research Use Only. Not for Use In Diagnostic Procedures. #CancerResearch #HER2 #LiquidBiopsy

This #BreastCancerAwarenessMonth, we showcase three key therapeutic approaches that are reshaping our understanding of HER2+ breast cancer. #CancerResearch #TranslationalMedicine

Innovation and collaboration took centre stage at #CLuB24! We were honoured to hear and participate in insightful presentations on harnessing liquid biopsy for circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) analysis. As we collectively look beyond enumeration, it was exciting to explore new ideas for downstream analysis including hot topics like DNA methylation. Trinity College Dublin also gave an excellent presentation on how they are leveraging the Parsortix® system across various cancer types. Explore their recent comparison study that highlighted the Parsortix® PR1 system as the top choice for CTC enrichment in lung cancer: https://lnkd.in/eR4D2cZ5 Together, we are pioneering the future of personalised medicine in oncology! #CancerResearch #Innovation #PersonalisedMedicine 

Unlock accurate, repeatable, and precise PD-L1 CTC insights with ANGLE. Accelerate your research with: • Highly accurate, repeatable and precise PDL1 CTC insights   • Minimally invasive, longitudinal monitoring of PDL1 status on variety of CTCs   • Early competitive advantage by understanding therapeutic response sooner   • Optimised patient selection   • Reduced trial size costs and time Discover ANGLE's end-to-end PDL1 CTC testing solution: https://lnkd.in/eSFcEuMk #PrecisionOncology #TranslationalMedicine #LiquidBiopsy For Research Use Only. Not for Use In Diagnostic Procedures.

As we reflect on the evolution of HER2, we are reminded of the critical role that research and innovation play in advancing cancer care. Explore five key HER2 milestones in breast cancer research. #CancerResearch #HER2 #BreastCancerAwarenessMonth

Experience customised CTC testing tailored to your research requirements. Portrait® Flex is an immunofluorescence assay for the identification of epithelial, mesenchymal and epithelial-to-mesenchymal transition CTCs, plus an optional additional biomarker developed specifically for your study needs.  Our scientific experts are on hand to support your research requirements from ANGLE’s GCP-compliant laboratories. Learn more: https://lnkd.in/eAh_YRAZ  #LiquidBiopsy #PrecisionOncology #CancerResearch

Interested in liquid biopsy for cancer research? Don’t miss Mariacristina Ciccioli, ANGLE’s Head of Assay Development, at The All-Ireland Cancer Liquid Biopsies Consortium (CLuB), where she will explore how the Parsortix system is transforming liquid biopsy analysis. #CLuB24 #LiquidBiopsy #CancerResearch

Liquid biopsy could transform how we detect the DNA Damage Response (DDR). At the 4th Exploring DNA Repair Pathways as Targets for Cancer Therapy conference, Amina Mezni from our R&D team, was proud to present our findings on the potential of liquid biopsy for detecting DDR biomarkers in circulating tumour cells. Delve into the research here: https://lnkd.in/eqkkVmsJ #DDR #LiquidBiopsy #CancerResearch